US Stock Insider Trading | HeartFlow Discloses Three Insider Transactions on March 12

K-LinePoet · 2026-03-13T02:11:45+00:00

HeartFlow (HTFL) disclosed multiple insider transactions on March 12, 2026, including buy and sell activities by directors and executives, including director Farquhar John C.M. Farquhar sold 12,800 shares on March 10 and purchased 2,631 shares on March 6. HeartFlow focuses on providing accurate coronary artery disease diagnostic solutions using AI and software.

K-LinePoet

2026-03-13 02:11:45

Abstract generation in progress

On March 12, 2026, Heartflow (HTFL) disclosed three insider transactions. Director Farquhar John C.M. sold 12,800 shares on March 11, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 12, 2026	Director	Farquhar John C.M.	March 6, 2026	Buy	2,631	16.15	$42,500
March 12, 2026	Director	BARABE TIMOTHY C	March 11, 2026	Buy	8,667	2.22	$19,200
March 12, 2026	Director	Farquhar John C.M.	March 10, 2026	Sell	12,800	22.66	$290,900
March 6, 2026	Director	Cullivan Julie A	March 5, 2026	Sell	9,122	25.00	$228,100
February 19, 2026	Director	BARABE TIMOTHY C	February 17, 2026	Buy	2,497	8.33	$20,800
February 17, 2026	Executive	Rogers Campbell	February 12, 2026	Buy	27,300	2.22	$60,600
February 17, 2026	Executive	Rogers Campbell	February 12, 2026	Sell	65,200	24.49	$1,595,500
February 17, 2026	Executive	Rogers Campbell	February 12, 2026	Buy	39,700	8.33	$33,100
February 10, 2026	Executive	Verghese Vikram	February 6, 2026	Sell	542	27.74	$15,000
February 10, 2026	Director	Farquhar John C.M.	February 10, 2026	Sell	22,600	27.46	$619,600

[Company Profile]

Heartflow, Inc. was incorporated in 2007 under Delaware law. Heartflow pioneered the use of software and artificial intelligence to provide a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease, which is a leading cause of death worldwide. Their new platform leverages AI and advanced computational fluid dynamics to create personalized 3D models of patients’ hearts from a single coronary CT angiography scan, a specialized imaging type that provides detailed images of the heart arteries. The Heartflow platform offers insights into blood flow, stenosis, plaque volume, and composition, overcoming the limitations of traditional non-invasive imaging tests that rely on indirect measures of coronary artery disease and often result in higher false negatives and positives, as demonstrated by their precise testing.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes